Skip to main content
Vitrolife logo

Vitrolife — Investor Relations & Filings

Ticker · VITR ISIN · SE0011205202 LEI · 5493001WDZMONMSPPR49 ST Manufacturing
Open in API
Filings indexed 656 across all filing types
Latest filing 2019-04-02 Annual Report
Country SE Sweden
Listing ST VITR

About Vitrolife

https://www.vitrolife.com/

Vitrolife is a global company focused on reproductive health, providing medical devices and genetic testing services primarily to In Vitro Fertilization (IVF) clinics. The company develops, produces, and markets a comprehensive portfolio of products and solutions that support the entire assisted reproduction treatment journey, from oocyte retrieval and sperm preparation to fertilization, embryo culture, evaluation, transfer, and cryopreservation. With a strong emphasis on quality control, innovation, and clinical support, Vitrolife aims to improve treatment outcomes and operational efficiency for its partners. The company also offers educational resources and training for professionals through its Vitrolife Academy.

Recent filings

Filing Released Lang Actions
Annual Report 2018
Annual Report Classification · 100% confidence The document is explicitly titled 'ANNUAL REPORT 2018' and contains comprehensive financial information, including a CEO's comments, business unit reviews, a 5-year summary, income statements, statements of financial position, cash-flow statements, and an auditor's report. It covers the full fiscal year and provides detailed financial and operational analysis, fitting the definition of an Annual Report (10-K). FY 2018
2019-04-02 English
Notice of Annual General Meeting of Vitrolife AB (publ)
AGM Information Classification · 100% confidence The document is explicitly titled "Notice to attend the Annual General Meeting of VITROLIFE AB (publ)" and details the date, location, registration procedures, and the full agenda for the meeting (Items 1 through 18). The agenda covers standard AGM topics like election of the chairman, approval of accounts, discharge from liability, election of the Board, and resolutions on remuneration and share authorizations. This content perfectly matches the definition of materials shared during an Annual General Meeting. Although the agenda mentions the presentation of the annual accounts and audit report (Item 8), the document itself is the formal notice and invitation to the meeting, not the full 10-K or AR document. Therefore, the appropriate classification is AGM-R (AGM Information).
2019-03-26 English
Kallelse till årsstämma i Vitrolife AB (publ)
AGM Information Classification · 100% confidence The document is titled "Kallelse till årsstämma i VITROLIFE AB (publ)" which translates to "Notice of Annual General Meeting in VITROLIFE AB (publ)". It details the date, time, location, registration procedures, and a detailed agenda (Dagordning) for the meeting, including proposals for board elections, dividend approval, and remuneration guidelines. This content is characteristic of a formal notice calling shareholders to an Annual General Meeting (AGM). The appropriate code is AGM-R.
2019-03-26 Swedish
EmbryoScope+ approved for sales in China
Regulatory Filings Classification · 95% confidence The document is a short press release dated March 15, 2019, announcing that Vitrolife AB received market approval for its EmbryoScope+ product in China. It details a specific business event (product approval in a major market) and includes contact information and a concluding statement about compliance with EU Market Abuse Regulation regarding public disclosure. This type of announcement, which is not a formal financial report (like 10-K, IR, ER) nor a specific corporate action (like DIV, CAP, DIRS), fits best under the general category for regulatory announcements that do not fit elsewhere, which is Regulatory Filings (RNS). It is too specific for a general 'Press Release' category and does not relate to dividends, management changes, or financial results.
2019-03-15 English
EmbryoScope+ godkänd för försäljning i Kina
Regulatory Filings Classification · 95% confidence The document is a short press release dated March 15, 2019, announcing that Vitrolife AB has received market approval in China for its EmbryoScope+ product. It contains key highlights, quotes from management, and contact information. It is not a comprehensive annual report (10-K), an interim report (IR), an earnings release (ER), or a transcript (CT). Since it is a specific announcement regarding a regulatory/market approval event, it fits best under the general 'Regulatory Filings' category (RNS) as it is a formal public disclosure required under market abuse regulations, but it is not one of the highly specific categories like DIRS, DIV, or MANG. Given the nature of the announcement (market approval), RNS is the most appropriate general regulatory disclosure category.
2019-03-15 Swedish
Major Shareholding Notification 2019
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding for Bure Equity AB (publ) in Vitrolife AB. Specifically, it shows the 'Before the transaction' and 'After the transaction' share counts, the reason for the notification ('Sell'), and the resulting percentage of voting rights (19%). This structure is characteristic of a Major Shareholding Notification, where an entity reports crossing ownership thresholds (or changes within those thresholds) as required by financial regulators. This aligns directly with the definition for Major Shareholding Notification (MRQ). The document is not a full annual report (10-K), an earnings release (ER), or a director's dealing report (DIRS), as it concerns a major institutional holder, not an executive's personal trade.
2019-03-07 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.